CELG : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    January 11, 2014
    The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December ...
  3. Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - ...

    January 8, 2014
    Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook
  4. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  5. Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day

    October 31, 2013
    Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day
  6. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  7. Amgen Sweetens The Bid And Secures Onyx

    August 26, 2013
    Amgen finalizes a value-additive deal for Onyx
  8. Pfizer Looking A Little Tired

    July 30, 2013
    Pfizer gets a boost from better margins, but the growth outlook is pretty feeble.
  9. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  10. Onyx Pharma Turns Down Amgen offer - Analyst Blog

    July 1, 2013
    Onyx rejected Amgen's takeover bid.
  11. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  12. Celgene presents Revlimid Data - Analyst Blog

    June 26, 2013
    Celgene presented data on in patients suffering from various forms of non-Hodgkin's lymphoma
  13. Pluristem Updates on IC Study - Analyst Blog

    June 20, 2013
    Pluristem recently announced that it has provided the FDA with additional information regarding the clinical trials for intermittent ...
  14. Good News for Celgene's Pipeline - Analyst Blog

    June 18, 2013
    Celgene presented positive results on apremilast from a phase II study.
  15. Data on BMY/ AbbVie's elotuzumab - Analyst Blog

    June 17, 2013
    Bristol-Myers and partner AbbVie presented data on elotuzumab from a phase II study.
  16. Apremilast Data Presented by Celgene - Analyst Blog

    June 14, 2013
    Celgene presented data from the PALACE 3 study on apremilast.
  17. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  18. ImmunoGen Progresses with IMGN901 - Analyst Blog

    February 14, 2013
    ImmunoGen, Inc. (IMGN) recently announced that it has finished enrolling patients for the initial stage of the two-stage ...
  19. Priority FDA Review for Celgene Drug - Analyst Blog

    February 12, 2013
    Recently, Celgene Corporation (CELG) announced that the US Food and Drug Administration (FDA) will review the supplemental ...
  20. US Approval for Celgene's Pomalyst - Analyst Blog

    February 11, 2013
    The US Food and Drug Administration (FDA) recently delivered encouraging news to Celgene Corporation (CELG) by approving ...
  21. Pluristem Moves to New Facility - Analyst Blog

    January 31, 2013
    Pluristem Therapeutics, Inc. (PSTI) recently announced that it has taken possession of its new state-of-the-art facility ...
  22. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  23. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  24. Safest Way to Play Biotech - Cook`s Kitchen

    January 25, 2013
    Investing in biotechnology can be exciting, profitable, and loaded with land mines. For every company that hits the jackpot ...
  25. Good news for Celgene - Analyst Blog

    January 25, 2013
    Celgene Corporation (CELG) recently announced that its oncology drug, Abraxane, has performed well in a phase III study (MPACT: ...
  26. InterMune Prices Public Offerings - Analyst Blog

    January 18, 2013
    InterMune Inc. (ITMN) recently priced its concurrent underwritten public offerings of convertible senior notes and shares ...
  27. InterMune to Raise Funds - Analyst Blog

    January 16, 2013
    InterMune Inc. (ITMN) recently announced its intention to raise funds through concurrent underwritten public offerings. InterMune ...
  28. Celgene Hits 52-Week High - Analyst Blog

    January 15, 2013
    Shares of Celgene Corporation (CELG) hit a 52-week high of $97.71 almost at the end of the trading session on Jan 14. This ...
  29. Pluristem Progresses with New Facility - Analyst Blog

    January 7, 2013
    Israel-based Pluristem Therapeutics, Inc. (PSTI) recently announced the initiation of the final validation steps for its ...
  30. Celgene Among Healthcare's Biggest Movers on January 2, 2013

    January 2, 2013
    The market is having a good day so far: the Nasdaq has risen 2.3%; the S&P 500 is up 1.8%; and the Dow has climbed 1.9%. ...
  31. BMY/ABT Present Oncology Data - Analyst Blog

    December 12, 2012
    Bristol-Myers Squibb Company (BMY) and partner Abbott Laboratories (ABT) recently presented data on their oncology candidate ...
  32. Celgene and More Big Movers in Healthcare on December 10, 2012

    December 10, 2012
    On a good day for the market, the Nasdaq is trading up 0.6%, the S&P 500 is up 0.2% and the Dow has increased 0.3%. The healthcare ...
  33. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  34. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  35. Celgene's Apremilast Encourages - Analyst Blog

    November 15, 2012
    Celgene Corporation (CELG) recently announced encouraging results on its candidate apremilast from a phase III study (PALACE-1: ...
  36. Gilead and Other Big Movers on the Nasdaq on November 12, 2012

    November 12, 2012
    Currently, the Nasdaq has declined 0.1%, the S&P 500 is unchanged and the Dow has slipped 0.1%. The recent surge in popularity ...
  37. Gilead Among Healthcare's Biggest Movers on November 12, 2012

    November 12, 2012
    The Nasdaq has decreased 0.1%, the S&P 500 has moved little and the Dow is trading down 0.1% so far today. The healthcare ...
  38. Loss at ITMN Narrower than Expected - Analyst Blog

    November 8, 2012
    InterMune Inc.'s (ITMN) third-quarter loss per share of 70 cents was narrower than the Zacks Consensus loss Estimate of 84 ...
  39. Onyx Enrolls FOCUS Patients - Analyst Blog

    October 22, 2012
    Onyx Pharmaceuticals, Inc. (ONXX) recently announced that it has finished enrolling patients for the phase III FOCUS (CarFilzOmib ...
  40. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down 1.1%. ...
  41. Eli Lilly and Other Healthcare Stocks Making Big Moves on October ...

    October 10, 2012
    The Nasdaq has been relatively flat, the S&P 500 is down 0.2% and the Dow has decreased 0.5% so far today. The healthcare ...
  42. Gilead Among Healthcare's Biggest Movers on October 2, 2012

    October 2, 2012
    So far today, the Nasdaq has climbed 0.4%, the S&P 500 is up 0.1% and the Dow is trading down 0.2%. The healthcare sector ...
  43. FDA Panel to Review Celgene Drug - Analyst Blog

    September 20, 2012
    Celgene Corporation (CELG) recently announced that Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration ...
  44. Celgene Among Healthcare's Biggest Movers on September 10, 2 ...

    September 10, 2012
    The Nasdaq has slipped 0.6%, the S&P 500 is unchanged and the Dow is trading up 0.1% after the morning's trading. The healthcare ...
  45. Biogen Idec and Other Big Movers In Healthcare on September 6, ...

    September 6, 2012
    The morning has been good for the market. The Nasdaq has risen 1.9%; the S&P 500 is up 1.8%; and the Dow has moved up 1.7%. ...
  46. Celgene and More Big Movers in Healthcare on August 31, 2012

    August 31, 2012
    The market is on the rise this morning. The Nasdaq has climbed 0.8%; the S&P 500 is up 0.8%; and the Dow has risen 0.9%. ...
  47. Today's Major Healthcare Sector Movers

    July 13, 2012
    The Nasdaq has climbed 0.5%, the S&P 500 is up 0.3% and the Dow has risen 0.5% on a good day for the market so far. The healthcare ...
  48. Big Movers on the Healthcare Sector Today

    July 9, 2012
    After the morning's trading, the Nasdaq is up 0.2%, the S&P 500 is up 0.1% and the Dow has slipped 0.1%. The healthcare sector ...
  49. New Lease Agreements for Alexandria - Analyst Blog

    June 8, 2012
    Alexandria Real Estate Equities, Inc. (ARE), a real estate investment trust (REIT), recently entered into long-term agreements ...
  50. The Trend In Rising Cancer Incidences

    June 5, 2012
    As the world continues to modernize and grow, global cancer incidences are expected to increase exponentially and pharmaceutical ...
  51. FDA Panel to Review Onyx Drug - Analyst Blog

    May 7, 2012
    Onyx Pharmaceuticals Inc. (ONXX) recently announced that the U.S. Food and Drug Administration's (FDA) advisory committee ...
  52. Playing Defense with Growth

    April 5, 2012
    Fast growers are starting to outperform value stocks more sensitive to the economic climate, writes MoneyShow.com senior ...
  53. Playing A Biotech Breakout

    February 15, 2012
    Strong pipelines for the biotech sector as well as a wave of merger activity, have investors flocking to the stocks.
  54. Should Pfizer Forget R&D Altogether?

    November 2, 2011
    Pfizer has to convince the Street that it can still grow, but the stock is cheap for now.
  55. Are Buybacks A Bad Sign?

    August 24, 2011
    Investors celebrate buybacks, but there is a cost to every decision.
  56. Four Drug Stocks To Watch On Thursday

    July 27, 2011
    Here are four drug stocks investors should watch heading into the second-half of the week.
  57. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  58. A Look Back At Biotech

    December 28, 2010
    Big biotechs had a mixed year, with concerns about R&D costs and product sales. The stocks may have seen the worst of it, ...
  59. 3 Stocks That Wall Street Analysts Love

    August 12, 2010
    These three stocks boast the highest percentage analyst buy ratings on the S&P 500.
  60. Is Another Wave Of Biotech M&A On The Way?

    July 2, 2010
    If biotech companies are buying each other, should investors get in on the action?
  61. What Ails Amgen?

    June 30, 2010
    Amgen is being treated like just another Big Pharma laggard, but analysis suggests there is more growth potential here.
  62. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
  63. 4 Stocks The Insiders Are Buying

    June 9, 2010
    The recent pullback has provided insiders with the opportunity to pick up shares of their own stock at cheaper prices.
  64. Searching For Growth And Value in Biotech

    March 9, 2010
    With health care reform ever present in the news, what are the prospects for biotech firms?
  65. Biotech Poised to Disappoint

    April 7, 2009
    The recent wave of big pharma acquisitions does not live up to hype.
  66. Sequenom Stock Testing Signs Of Life

    January 14, 2009
    Sequenom stock has climbed on the success of a new diagnostic product. Is there any place to go but "down"?
  67. 5 Biotech Stocks To Watch In 2009

    December 30, 2008
    When the market starts to look sickly, can you turn to Biotechs to inject health into your portfolio? Here are five stocks ...
  68. Stem Cell Regeneration For Wounded Bulls

    October 17, 2008
    In the present volatile market, risk-averse investors may want to consider stem cell stocks.
  69. Biotech ETFs Under The Microscope

    July 24, 2008
    Biotech ETFs have been immune to the falling stock market. We examine three top performing funds to find a surprising long-term ...
  70. Biotech Back From The Dead

    June 27, 2008
    Biotech has been sickly for more than a year, but the sector is showing signs of life. Learn which smaller names are gaining ...
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center